CONTACT US
Home > Inhibitors/Agonists>HDAC> > Sodium 4-phenylbutyrate
1716-12-7-Sodium 4-phenylbutyrate Sodium 4-phenylbutyrate

Sodium 4-phenylbutyrate

For research use only. Not for therapeutic Use.

  • CAT Number: I002242
  • CAS Number: 1716-12-7
  • Molecular Formula: C₁₀H₁₁O₂ . Na
  • Molecular Weight: 186.20
  • Purity: 98%
Inquiry Now
Related products: Terpinyl Acetate     Demethyleneberberine     Efetaal    

Sodium 4-phenylbutyrate (Cat No.:I002242) is also known for its histone deacetylase (HDAC) inhibitory activity. HDACs are enzymes involved in the regulation of gene expression by modifying histone proteins. By inhibiting HDACs, sodium 4-phenylbutyrate can increase histone acetylation, leading to changes in gene expression patterns. This mechanism has been explored for its potential therapeutic applications, particularly in the field of cancer treatment. Sodium 4-phenylbutyrate has shown promise as an HDAC inhibitor in preclinical and clinical studies, demonstrating its potential as an anticancer agent by promoting cell cycle arrest, inducing apoptosis, and inhibiting angiogenesis.


Catalog Number I002242
CAS Number 1716-12-7
Synonyms

sodium;4-phenylbutanoate

Molecular Formula C₁₀H₁₁O₂ . Na
Purity 98%
Target HDAC
Target Protein

P08648

Solubility H2O: ≥ 23.5 mg/mL
Appearance Solid
Storage Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
IC50 IC50: 1-5 uM
IUPAC Name sodium;4-phenylbutanoate
InChI InChI=1S/C10H12O2.Na/c11-10(12)8-4-7-9-5-2-1-3-6-9;/h1-3,5-6H,4,7-8H2,(H,11,12);/q;+1/p-1
InChIKey VPZRWNZGLKXFOE-UHFFFAOYSA-M
SMILES C1=CC=C(C=C1)CCCC(=O)[O-].[Na+]
Reference

<br />
1:Effect of sodium phenylbutyrate on the sensitivity of PC3/DTX-resistant prostate cancer cells to docetaxel]. Xu YW, Zheng SB, Chen BS, Wen Y, Zhu SW.Nan Fang Yi Ke Da Xue Xue Bao. 2017 Novemer 20;37(1):130-134. Chinese. PMID: 28109113<br />
2:Averting the foul taste of pediatric medicines improves adherence and can be lifesaving – Pheburane<sup>&reg;</sup> (sodium phenylbutyrate). Koren G, Rieder MJ, Amitai Y.Patient Prefer Adherence. 2016 Oct 21;10:2141-2144. eCollection 2016. Review. PMID: 27799750 Free PMC Article<br />
3:Beneficial Effects of Sodium Phenylbutyrate Administration during Infection with Salmonella enterica Serovar Typhimurium. Jellbauer S, Perez Lopez A, Behnsen J, Gao N, Nguyen T, Murphy C, Edwards RA, Raffatellu M.Infect Immun. 2016 Aug 19;84(9):2639-52. doi: 10.1128/IAI.00132-16. Print 2016 Sep. PMID: 27382022 Free PMC Article<br />
4:Sodium phenylbutyrate antagonizes prostate cancer through the induction of apoptosis and attenuation of cell viability and migration. Xu Y, Zheng S, Chen B, Wen Y, Zhu S.Onco Targets Ther. 2016 May 12;9:2825-33. doi: 10.2147/OTT.S101794. eCollection 2016. PMID: 27274278 Free PMC Article<br />
5:Lipopolysaccharide-Induced Behavioral Alterations Are Alleviated by Sodium Phenylbutyrate via Attenuation of Oxidative Stress and Neuroinflammatory Cascade. Jangra A, Sriram CS, Lahkar M.Inflammation. 2016 Aug;39(4):1441-52. doi: 10.1007/s10753-016-0376-5. PMID: 27192986<br />
6:Switch from Sodium Phenylbutyrate to Glycerol Phenylbutyrate Improved Metabolic Stability in an Adolescent with Ornithine Transcarbamylase Deficiency. Laemmle A, Stricker T, H&auml;berle J.JIMD Rep. 2017;31:11-14. doi: 10.1007/8904_2016_551. Epub 2016 Mar 22. PMID: 27000017 Free PMC Article<br />
7:Sodium Phenylbutyrate and Edaravone Abrogate Chronic Restraint Stress-Induced Behavioral Deficits: Implication of Oxido-Nitrosative, Endoplasmic Reticulum Stress Cascade, and Neuroinflammation. Jangra A, Sriram CS, Dwivedi S, Gurjar SS, Hussain MI, Borah P, Lahkar M.Cell Mol Neurobiol. 2017 Jan;37(1):65-81. doi: 10.1007/s10571-016-0344-5. Epub 2016 Feb 17. PMID: 26886752<br />
8:Long-Term Follow-Up on a Cohort Temporary Utilization Authorization (ATU) Survey of Patients Treated with Pheburane (Sodium Phenylbutyrate) Taste-Masked Granules. Kibleur Y, Guffon N.Paediatr Drugs. 2016 Apr;18(2):139-44. doi: 10.1007/s40272-015-0159-8. Review. PMID: 26747635<br />
9:Study of Antitumor Activity of Sodium Phenylbutyrate, Histon Deacetylase Inhibitor, on Ehrlich Carcinoma Model. Fadeev NP, Kharisov RI, Kovan/&#39;ko EG, Pustovalov YI.Bull Exp Biol Med. 2015 Sep;159(5):652-4. doi: 10.1007/s10517-015-3039-x. Epub 2015 Oct 15. PMID: 26468021<br />
10:Treatment of Paraneoplastic Hyperammonemia in Fibrolamellar Hepatocellular Carcinoma With Oral Sodium Phenylbutyrate. Bender HU, Staudigl M, Schmid I, F&uuml;hrer M.J Pain Symptom Manage. 2015 Jun;49(6):e8-10. doi: 10.1016/j.jpainsymman.2015.03.007. Epub 2015 Apr 16. No abstract available. PMID: 25891666

Request a Quote